- call +1-201-465-4211
- email sales@mrinsights.biz
Growing demand for obesity is one of the recent trends in the global Anti-Obesity Prescription Drugs market. Moreover, this trend is further anticipated to drive the global Anti-Obesity Prescription Drugs market over the forecast period. Furthermore, growing obesity due unhealthy food and lifestyle such as intake of drugs due to stress, alcohol leads to growing demand for obesity management resulting in growth of this trend.
Scope of the Report:
This report focuses on the Anti-Obesity Prescription Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The worldwide market for Anti-Obesity Prescription Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
F Hoffmann La Roche Ltd
Orexigen Therapeutics, Inc
Novo Nordisk A/s
Arena Pharmaceuticals, Inc
Glaxosmithkline
Vivus, Inc
Boehringer Ingelheim
Alizyme
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Orlistat
Phentermine and Topiramate
Bupropion and Naltrexone
Lorcaserin
Liraglutide
Market Segment by Applications, can be divided into
Pediatric
Adult
There are 15 Chapters to deeply display the global Anti-Obesity Prescription Drugs market.
Chapter 1, to describe Anti-Obesity Prescription Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Anti-Obesity Prescription Drugs, with sales, revenue, and price of Anti-Obesity Prescription Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-Obesity Prescription Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Anti-Obesity Prescription Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Anti-Obesity Prescription Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Anti-Obesity Prescription Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Orlistat
1.2.2 Phentermine and Topiramate
1.2.3 Bupropion and Naltrexone
1.2.4 Lorcaserin
1.2.5 Liraglutide
1.3 Market Analysis by Applications
1.3.1 Pediatric
1.3.2 Adult
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 F Hoffmann La Roche Ltd
2.1.1 Business Overview
2.1.2 Anti-Obesity Prescription Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 F Hoffmann La Roche Ltd Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Orexigen Therapeutics, Inc
2.2.1 Business Overview
2.2.2 Anti-Obesity Prescription Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Orexigen Therapeutics, Inc Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novo Nordisk A/s
2.3.1 Business Overview
2.3.2 Anti-Obesity Prescription Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Novo Nordisk A/s Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Arena Pharmaceuticals, Inc
2.4.1 Business Overview
2.4.2 Anti-Obesity Prescription Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Arena Pharmaceuticals, Inc Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Glaxosmithkline
2.5.1 Business Overview
2.5.2 Anti-Obesity Prescription Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Glaxosmithkline Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Vivus, Inc
2.6.1 Business Overview
2.6.2 Anti-Obesity Prescription Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Vivus, Inc Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Boehringer Ingelheim
2.7.1 Business Overview
2.7.2 Anti-Obesity Prescription Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Boehringer Ingelheim Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Alizyme
2.8.1 Business Overview
2.8.2 Anti-Obesity Prescription Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Alizyme Anti-Obesity Prescription Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Anti-Obesity Prescription Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Anti-Obesity Prescription Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Anti-Obesity Prescription Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Anti-Obesity Prescription Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Anti-Obesity Prescription Drugs Market Analysis by Regions
4.1 Global Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Anti-Obesity Prescription Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
4.5 South America Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
5 North America Anti-Obesity Prescription Drugs by Countries
5.1 North America Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Anti-Obesity Prescription Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Anti-Obesity Prescription Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
6 Europe Anti-Obesity Prescription Drugs by Countries
6.1 Europe Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Anti-Obesity Prescription Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Anti-Obesity Prescription Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
6.3 UK Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
6.4 France Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Anti-Obesity Prescription Drugs by Countries
7.1 Asia-Pacific Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Anti-Obesity Prescription Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Anti-Obesity Prescription Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
7.5 India Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
8 South America Anti-Obesity Prescription Drugs by Countries
8.1 South America Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Anti-Obesity Prescription Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Anti-Obesity Prescription Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Anti-Obesity Prescription Drugs by Countries
9.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Anti-Obesity Prescription Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Anti-Obesity Prescription Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Anti-Obesity Prescription Drugs Sales and Growth Rate (2013-2018)
10 Global Anti-Obesity Prescription Drugs Market Segment by Type
10.1 Global Anti-Obesity Prescription Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Anti-Obesity Prescription Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Anti-Obesity Prescription Drugs Revenue and Market Share by Type (2013-2018)
10.2 Orlistat Sales Growth and Price
10.2.1 Global Orlistat Sales Growth (2013-2018)
10.2.2 Global Orlistat Price (2013-2018)
10.3 Phentermine and Topiramate Sales Growth and Price
10.3.1 Global Phentermine and Topiramate Sales Growth (2013-2018)
10.3.2 Global Phentermine and Topiramate Price (2013-2018)
10.4 Bupropion and Naltrexone Sales Growth and Price
10.4.1 Global Bupropion and Naltrexone Sales Growth (2013-2018)
10.4.2 Global Bupropion and Naltrexone Price (2013-2018)
10.5 Lorcaserin Sales Growth and Price
10.5.1 Global Lorcaserin Sales Growth (2013-2018)
10.5.2 Global Lorcaserin Price (2013-2018)
10.6 Liraglutide Sales Growth and Price
10.6.1 Global Liraglutide Sales Growth (2013-2018)
10.6.2 Global Liraglutide Price (2013-2018)
11 Global Anti-Obesity Prescription Drugs Market Segment by Application
11.1 Global Anti-Obesity Prescription Drugs Sales Market Share by Application (2013-2018)
11.2 Pediatric Sales Growth (2013-2018)
11.3 Adult Sales Growth (2013-2018)
12 Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
12.1 Global Anti-Obesity Prescription Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Anti-Obesity Prescription Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
12.2.2 Europe Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
12.2.4 South America Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Anti-Obesity Prescription Drugs Market Forecast (2018-2023)
12.3 Anti-Obesity Prescription Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Anti-Obesity Prescription Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Anti-Obesity Prescription Drugs Market Share Forecast by Type (2018-2023)
12.4 Anti-Obesity Prescription Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Anti-Obesity Prescription Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Anti-Obesity Prescription Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Anti-Obesity Prescription Drugs Picture
Table Product Specifications of Anti-Obesity Prescription Drugs
Figure Global Sales Market Share of Anti-Obesity Prescription
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
